{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-002721","form_type":"8-K","ticker":"OLMA","cik":"0001750284","company_name":"Olema Pharmaceuticals, Inc.","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.391683+00:00","generated_at":"2026-06-07T02:25:12.292178+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Olema nominates OP-3136, KAT6 inhibitor for breast cancer; IND submission targeted by end of 2024","bullets":["OP-3136 is an orally bioavailable, potent KAT6A/B-selective inhibitor for ER+ breast cancer.","Preclinical data show dose-dependent tumor regression alone and synergy with CDK4/6 or palazestrant.","IND-enabling studies initiated; goal to file IND with FDA by end of 2024.","Aurigene receives $5M milestone payment upon initiation of IND-enabling studies."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-002721","json":"https://secwatch.observer/filing/0000950170-24-002721.json","markdown":"https://secwatch.observer/filing/0000950170-24-002721.md","text":"https://secwatch.observer/filing/0000950170-24-002721.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750284/000095017024002721/0000950170-24-002721-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750284/000095017024002721/olma-20240108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:25:12.292178+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}